Tamoxifen treatment and malignant endometrial tumors - What's new?

Harefuah

Volumn 145, Issue 3 SPEC. ISS., 2006, Pages 219-222

  Perlman, Sharon ^a   Vaisbuch, Edi ^a   Ben Arie, Alon ^a  

^a NONE

Author keywords

Breast; Carcinoma; Endometrium; Estrogen; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAMOXIFEN;

ENDOMETRIUM TUMOR; FEMALE; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; TAMOXIFEN;

EID: 33646098412     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Oehler MK, Brand A & Wain GV, Molecular genetics and endometrial cancer, J Br Menopause Soc, 2003; 9: 27-31.
2. Bissett D, Davis JA & Geprge WD, Gynecological monitoring during tamoxifen therapy. Lancet, 1994; 344: 1244.
3. Fisher B, Costantino JP, Redmond CK & al, Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst, 1994; 86: 527-37.
4. Barakat RR, Wong G, Curtin JP & al, Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol, 1994; 55: 164-8.
5. Magriples U, Naftolin F, Schwartz PE & al, High-grade endometrial carcinoma in Tamoxifen treated breast cancer patients. Clin Oncol, 1993, 11; 485-490.
6. McCluggagae WG, Sumathi VP & McManus DT, Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of S cases, including 2 associated with tamoxifen therapy. Human Pathol, 2003, 34: 9 939-943.
7. Gottlieb S, Tamoxifen may increase risk of uterine sarcoma. BMJ, 2002; 325: 7.
8. Kloos I, Delaloge S, Pautier P & al, Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer, 2002; 12: 496-500.
9. Martin-Loeches M, Rius J & Orti RM, Uterine sarcoma associated with tamoxifen use: a case report. Eur J Gynecol Oncol, 2003; 24: 202-3.
10. Saga Y, Ohwada M, Kohno T & al, High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer, Int J Gynecol Cancer, 2003; 13: 690-2.
11. Pukkala E, Kyyronem P & Holli K, Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study. Int J Cancer, 2002; 100: 337-41.
12. Swerdlow AJ & Jones ME, Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst, 2005; 97: 375-84.
13. Prasad M, Wang H, Douglas W, Barakat RR & al, Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecol Oncol, 2005; 96: 25-31.
14. Ferguson SE, Olshen AB, Viale A & al, Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol, 2004; 92: 719-25.
15. Wilder JL, Shajahan S, Khattar NH & al, Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study, Gynecol Oncol, 2004; 92: 553-8.
16. Siufi AA, Cotrim G Da Silva ID & al, Effects of Tamoxifen therapy on the expression of p27 protein on the endometrium of women with primary breast cancer. Int J Oncol, 2003; 23: 1545-51.
17. Goldstein SR, Controversy about uterine effects and safety of SERMs: the saga continues. Menopause, 2002; 9: 381-4.
18. American College of Obsterticians and Gynecologists Committee on Practice Bulletins-Gynecology, ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999). Int J Gynaecol Obstet, 2002; 79: 289-98.
19. Franchi M, Ghezzi F, Donadello N & al, Endometrial thickness in tamoxifen treated patients: an independent predictor of endometrial disease. Obstet Gynecol, 1999; 93: 1004-8.
20. Fung MF, Reid A, Fought W & al, Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol, 2003; 91: 154-9.
21. Markovitch O, Tepper R, Fishman A & al, The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol, 2004; 95: 456-62.
22. Achiron R, Lipitz S, Sivan E & al, Changes mimicking endometrial neoplasia in postmenopausal tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Ultrasiund Obstet Gynecol, 1995; 6: 116-120.
23. Ascher SM, Imaoka I & Lage JM, Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology, 2000; 214: 29-38.
24. Bertelli G, Venturini M, Del Mastro L & al, Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat, 1998; 47: 41-6.
25. Renard F, Vosse M, Scagnol I & al, Aggressive endometrial carcinoma in abreast cancer patient treated with Tamoxifen with normal transvaginal Ultrasonography Case report. Eur J Gynaecol Oncol, 2002; 23: 25-8.
26. Garuti G, Cellani F, Colonnelli M & al, Hysteroscopically targeted biopsies compared with blind samplings in endometrial assessment of menopausal women taking tamoxifen for breast cancer. J Am Assoc Gynecol Laparosc, 2004; 11: 62-7.